Dendritic cell immunization induces nonprotective WT1-specific CTL responses in mouse

Journal of Immunotherapy

Volumn 30, Issue 2, 2007, Pages 140-149

  Ramírez, Francisco ^a   Ghani, Yasmeen ^a,b   Gao, Liquan ^a   Stauss, Hans ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cytotoxic T cells and dendritic cells; Tumor immunity; Vaccination

Indexed keywords

ARGINYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLTYROSYLLEUCINE; CYSTEINYLASPARAGINYLLYSYLARGINYLTYROSYLPHENYLALANYLLYSYLLEUCINE; DENDRITIC CELL VACCINE; EPITOPE; FREUND ADJUVANT; ISOLEUCYLSERYLGLUTAMINYLALANYLVALYLHISTIDYLALANYLALANYLHISTIDYLALANYL GLUTAMYLISOLEUCYLASPARAGINYLGLUTAMYLALANYLGLYCYLARGININE; LIPOPOLYSACCHARIDE; PHENYLALANYLALANYLPROLYLGLYCYLASPARAGINYLTYROSYLPROLYLALANYLLEUCINE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANIMALS; DENDRITIC CELLS; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNIZATION; IMMUNODOMINANT EPITOPES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGOPEPTIDES; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 34247574663     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211328.76266.81     Document Type: Article

References (43)

1. Theobald M, Biggs J, Hernández J, et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med. 1997;185:833-842.
2. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21:807-839.
3. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-3079.
4. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-1412.
5. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
6. Schorge JO, Miller YB, Qi LJ, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol. 2000;76:369-372.
7. Huang A, Campbell CE, Bonetta L, et al. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor. Science. 1990;250:991-994.
8. Buckler AJ, Pelletier J, Haber DA, et al. Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cel Biol. 1991;11:1707-1712.
9. + progenitors and downregulated early in the course of differentiation in vitro. Exp Hematol. 1997;25:945-950.
10. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
11. Müller L, Knights A, Pawelec G. Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemic cells. Hematol J. 2003;4:57-66.
12. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 2000;164:1873-1880.
13. Gaiger A, Reese V, Disis ML, et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
14. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol. 2000;20:195-202.
15. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
16. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 2002;100:3835-3837.
17. Kast WM, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A. 1991;88:2283-2287.
18. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. J Immunol. 1988;54:777-785.
19. Shimonkevitz R, Colon S, Kappler JW, et al. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol. 1984;133:2067-2074.
20. Hammerling GJ, Rusch E, Tada N, et al. Localization of allodeterminants on H-2Kb antigens determined with monoclonal antibodies and H-2 mutant mice. Proc Natl Acad Sci U S A. 1982;79:4737-4741.
21. Ozato K, Hansen TH, Sachs DH. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol. 1980;125:2473-2477.
22. Ljunggren HG, Karre K. Host resistance directed selectively against H-2 deficient lymphoma variants: analysis of the mechanism. J Exp Med. 1985;162:1745-1759.
23. Klein E, Klein G. Antigenic properties of lymphomas induced by the Moloney agent. J Natl Cancer Inst. 1964;32:547-568.
24. Carbone FR, Bevan MJ. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J Exp Med. 1989;169:603-612.
25. McCoy JL, Fefer A, Glynn JP. Comparative studies on the induction of transplantation resistance in BALB/c and C57BL/6 mice in three leukemia systems. Cancer Res. 1967;27:1743-1748.
26. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992;356:443-446.
27. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185:453-460.
28. Bellone M, Cantarella D, Castiglioni P, et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol. 2000;165:2651-2656.
29. Foster BA, Gingrich JR, Kwon ED, et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57:3325-3330.
30. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci U S A. 1996;93:13114-13118.
31. Franco A, Tilly DA, Gramaglia I, et al. Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat Immunol. 2000;1:145-150.
32. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulationg factor. J Exp Med. 1992;176:1693-1702.
33. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994;153:5586-5592.
34. Dahl AM, Beverley PCL, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol. 1996;157:239-246.
35. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 1995;182:255-260.
36. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med. 1995;12:1297-1302.
37. Alexander-Miller MA, Leggat GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA. 1996;93:4102-4107.
38. Zeh HJ, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999;162:989-994.
39. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99-107.
40. Azuma T, Makita M, Ninomiya K, et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol. 2002;116:601-603.
41. Scheibenbogen C, Anne L, Eckhard T, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukaemia. Blood. 2002;100:2132-2137.
42. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-13890.
43. Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-166.